Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996040066 - A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE

Publication Number WO/1996/040066
Publication Date 19.12.1996
International Application No. PCT/US1996/009951
International Filing Date 07.06.1996
Chapter 2 Demand Filed 07.01.1997
IPC
A61K 9/127 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
A61K 9/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/29 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
29Hepatitis virus
C07K 14/705 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
CPC
A61K 2039/55555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
A61K 39/0011
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
A61K 39/00117
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
001169Tumor associated carbohydrates
00117Mucins, e.g. MUC-1
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/292
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
29Hepatitis virus
292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Applicants
  • THE GOVERNORS OF THE UNIVERSITY OF ALBERTA [CA]/[CA] (AllExceptUS)
  • SAMUEL, John [IN]/[CA] (UsOnly)
  • KWON, Glen, S. [US]/[CA] (UsOnly)
Inventors
  • SAMUEL, John
  • KWON, Glen, S.
Agents
  • LEARN, June, M.
Priority Data
08/480,49907.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
(FR) PROCEDE POUR INDUIRE UNE REACTION IMMUNE SPECIFIQUE CONTRE TH1
Abstract
(EN)
A method is provided for treating a Th1 mediated disease state by administration to a subject of a slow release vehicle such as a liposome or microsphere formulation containing an antigenic peptide and a Th1 specific immunomodulator wherein the antigenic peptide contains a T cell epitope and is released from the vehicle at a rate in the range from about 10 to 2 weight percent of the peptide in 24 hours at 37 °C.
(FR)
L'invention concerne un procédé servant à traiter un état pathologique provoqué par Th1, par l'administration au patient d'un véhicule à libération lente, tel qu'une formulation à liposomes ou microsphères contenant un peptide antigénique et un immunomodulateur spécifique contre Th1, le peptide antigénique contenant un déterminant antigénique de cellule T et étant libéré du véhicule à une cadence située dans une plage de 10 à 2 % en poids du peptide en 24 heures à 37 °C.
Also published as
Latest bibliographic data on file with the International Bureau